<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0" xml:base="http://biomarkercommons.org">
<channel>
 <title>Biomarker Commons Funding Announcements</title>
 <link>http://biomarkercommons.org</link>
 <description />
 <language>en</language>
<image><url>http://users.feedblitz.com/6569a3af9c67a72f46e9e76706b31365/biomarkercommons-long.png</url><title>Biomarker Commons</title><link>http://biomarkercommons.org</link></image>
<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/biomarker-funding-announcements" /><feedburner:info uri="biomarker-funding-announcements" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/aushon-to-launch-new-multiplex-immunoassay-platform</feedburner:origLink>
 <title>Aushon to Launch New Multiplex Immunoassay Platform</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/0DUae701rSs/biomarker-news~Aushon-to-Launch-New-Multiplex-Immunoassay-Platform</link>
 <description>&lt;p&gt;Aushon announced its plans recently for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30609631/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30609631/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/0DUae701rSs" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/organization/aushon">Aushon</category>
 <category domain="http://biomarkercommons.org/term/immunoassay">immunoassay</category>
 <category domain="http://biomarkercommons.org/term/microarray">microarray</category>
 <category domain="http://biomarkercommons.org/term/multiplex">multiplex</category>
 <pubDate>Thu, 24 May 2012 19:05:42 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">745 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30609631/0/biomarker-news~Aushon-to-Launch-New-Multiplex-Immunoassay-Platform</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30609631/0/biomarker-news"&gt;&lt;p&gt;Aushon announced its plans recently for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30609631/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30609631/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/companion-diagnostics-budgets-exceed-1-million-as-companies-build-personalized-medicine-into-drug-development</feedburner:origLink>
 <title>Companion Diagnostics Budgets Exceed $1 Million as Companies Build Personalized Medicine into Drug Development Strategy</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/bn2ItSVANNA/biomarker-news~Companion-Diagnostics-Budgets-Exceed-Million-as-Companies-Build-Personalized-Medicine-into-Drug-Development-Strategy</link>
 <description>&lt;p&gt;As the drug discovery paradigm shifts away from mass-marketed products toward targeted treatments and the life sciences industry adjusts to an increasingly payer-driven environment, precision...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30557225/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30557225/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/bn2ItSVANNA" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/organization/cutting-edge-information">Cutting Edge Information</category>
 <category domain="http://biomarkercommons.org/term/budget">budget</category>
 <category domain="http://biomarkercommons.org/term/companion-diagnostic">companion diagnostic</category>
 <category domain="http://biomarkercommons.org/term/drug-development">drug development</category>
 <category domain="http://biomarkercommons.org/term/personalized-medicine">personalized medicine</category>
 <pubDate>Tue, 22 May 2012 19:13:11 +0000</pubDate>
 <dc:creator>Walter Jessen</dc:creator>
 <guid isPermaLink="false">703 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30557225/0/biomarker-news~Companion-Diagnostics-Budgets-Exceed-Million-as-Companies-Build-Personalized-Medicine-into-Drug-Development-Strategy</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30557225/0/biomarker-news"&gt;&lt;p&gt;As the drug discovery paradigm shifts away from mass-marketed products toward targeted treatments and the life sciences industry adjusts to an increasingly payer-driven environment, precision...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30557225/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30557225/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/mayo-clinic-researchers-discover-biomarkers-for-prostate-cancer-detection-recurrence</feedburner:origLink>
 <title>Mayo Clinic Researchers Discover Biomarkers for Prostate Cancer Detection, Recurrence</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/m6XfZRNzGiI/biomarker-news~Mayo-Clinic-Researchers-Discover-Biomarkers-for-Prostate-Cancer-Detection-Recurrence</link>
 <description>&lt;p&gt;Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30555590/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30555590/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/m6XfZRNzGiI" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/disease/cancer">cancer</category>
 <category domain="http://biomarkercommons.org/disease/prostate-cancer">prostate cancer</category>
 <category domain="http://biomarkercommons.org/organization/mayo-clinic">Mayo Clinic</category>
 <category domain="http://biomarkercommons.org/term/detection">detection</category>
 <category domain="http://biomarkercommons.org/term/dna-methylation">DNA methylation</category>
 <category domain="http://biomarkercommons.org/term/prostate">prostate</category>
 <category domain="http://biomarkercommons.org/term/prostate-cancer-recurrence">prostate cancer recurrence</category>
 <category domain="http://biomarkercommons.org/term/recurrence">recurrence</category>
 <pubDate>Tue, 22 May 2012 18:24:21 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">744 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30555590/0/biomarker-news~Mayo-Clinic-Researchers-Discover-Biomarkers-for-Prostate-Cancer-Detection-Recurrence</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30555590/0/biomarker-news"&gt;&lt;p&gt;Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30555590/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30555590/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/nextgen-introduces-new-generation-biomarker-products-for-brain-disorder-diagnostics</feedburner:origLink>
 <title>NextGen Introduces New Generation Biomarker Products for Brain Disorder Diagnostics</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/pDwHRJjqybc/biomarker-news~NextGen-Introduces-New-Generation-Biomarker-Products-for-Brain-Disorder-Diagnostics</link>
 <description>&lt;p&gt;NextGen Group Plc (AIM: NGG), an AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces the commercialisation of a new...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30555591/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30555591/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/pDwHRJjqybc" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/disease/central-nervous-system-disorders">central nervous system disorders</category>
 <category domain="http://biomarkercommons.org/organization/nextgen-sciences">NextGen Sciences</category>
 <category domain="http://biomarkercommons.org/term/central-nervous-system">central nervous system</category>
 <category domain="http://biomarkercommons.org/term/cerebrospinal-fluid">cerebrospinal fluid</category>
 <category domain="http://biomarkercommons.org/term/csf">CSF</category>
 <category domain="http://biomarkercommons.org/term/csfassay-human-b10">CSFassay-human B.1.0</category>
 <category domain="http://biomarkercommons.org/term/mass-spectrometry">mass spectrometry</category>
 <pubDate>Tue, 22 May 2012 17:57:06 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">743 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30555591/0/biomarker-news~NextGen-Introduces-New-Generation-Biomarker-Products-for-Brain-Disorder-Diagnostics</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30555591/0/biomarker-news"&gt;&lt;p&gt;NextGen Group Plc (AIM: NGG), an AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces the commercialisation of a new...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30555591/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30555591/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/genedata-and-roche-extend-collaboration-of-biomarker-discovery-for-personalized-healthcare</feedburner:origLink>
 <title>Genedata and Roche Extend Collaboration of Biomarker Discovery for Personalized Healthcare </title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/lfX6NJ8uZr4/biomarker-news~Genedata-and-Roche-Extend-Collaboration-of-Biomarker-Discovery-for-Personalized-Healthcare</link>
 <description>&lt;p&gt;Genedata, a leading provider of advanced software solutions for drug discovery and life science research, recently announced that Roche renewed the licensing agreement of Genedata Expressionist for...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30540069/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30540069/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/lfX6NJ8uZr4" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/organization/genedata">Genedata</category>
 <category domain="http://biomarkercommons.org/organization/roche">Roche</category>
 <category domain="http://biomarkercommons.org/term/biomarker-discovery">biomarker discovery</category>
 <category domain="http://biomarkercommons.org/term/data-management">data management</category>
 <category domain="http://biomarkercommons.org/term/genedata-expressionist-for-mass-spectrometry">Genedata Expressionist for Mass Spectrometry</category>
 <category domain="http://biomarkercommons.org/term/licensing">licensing</category>
 <category domain="http://biomarkercommons.org/term/mass-spectrometry">mass spectrometry</category>
 <category domain="http://biomarkercommons.org/term/omics">omics</category>
 <category domain="http://biomarkercommons.org/term/personalized-healthcare">personalized healthcare</category>
 <pubDate>Tue, 22 May 2012 02:01:56 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">742 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30540069/0/biomarker-news~Genedata-and-Roche-Extend-Collaboration-of-Biomarker-Discovery-for-Personalized-Healthcare</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30540069/0/biomarker-news"&gt;&lt;p&gt;Genedata, a leading provider of advanced software solutions for drug discovery and life science research, recently announced that Roche renewed the licensing agreement of Genedata Expressionist for...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30540069/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30540069/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/early-biomarker-for-pancreatic-cancer-identified</feedburner:origLink>
 <title>Early Biomarker for Pancreatic Cancer Identified </title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/W4AXXLzaOwk/biomarker-news~Early-Biomarker-for-Pancreatic-Cancer-Identified</link>
 <description>&lt;p&gt;Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391067/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391067/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/W4AXXLzaOwk" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/biomarker/peak1">PEAK1</category>
 <category domain="http://biomarkercommons.org/disease/cancer">cancer</category>
 <category domain="http://biomarkercommons.org/disease/pancreatic-cancer">pancreatic cancer</category>
 <category domain="http://biomarkercommons.org/disease/pancreatic-ductal-adenocarcinoma">pancreatic ductal adenocarcinoma</category>
 <category domain="http://biomarkercommons.org/organization/moores-cancer-center">Moores Cancer Center</category>
 <category domain="http://biomarkercommons.org/organization/san-diego-school-of-medicine">San Diego School of Medicine</category>
 <category domain="http://biomarkercommons.org/organization/university-of-california">University of California</category>
 <category domain="http://biomarkercommons.org/term/cell-proliferation">cell proliferation</category>
 <category domain="http://biomarkercommons.org/term/chemotherapy">chemotherapy</category>
 <category domain="http://biomarkercommons.org/term/drug-target">drug target</category>
 <category domain="http://biomarkercommons.org/term/gemitabine">Gemitabine</category>
 <category domain="http://biomarkercommons.org/term/immunotherapy">immunotherapy</category>
 <category domain="http://biomarkercommons.org/term/metastasis">metastasis</category>
 <category domain="http://biomarkercommons.org/term/therapeutic-target">therapeutic target</category>
 <category domain="http://biomarkercommons.org/term/trastuzumab">Trastuzumab</category>
 <pubDate>Tue, 15 May 2012 18:06:09 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">740 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30391067/0/biomarker-news~Early-Biomarker-for-Pancreatic-Cancer-Identified</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30391067/0/biomarker-news"&gt;&lt;p&gt;Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391067/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391067/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/new-us-patent-grant-for-valirx%E2%80%99s-cancer-screening-gene-biomarker</feedburner:origLink>
 <title>New US Patent Grant for ValiRx’s Cancer Screening Gene Biomarker</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/vwRIXQCHPR8/biomarker-news~New-US-Patent-Grant-for-ValiRx%e2%80%99s-Cancer-Screening-Gene-Biomarker</link>
 <description>&lt;p&gt;ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that a method for cancer screening, using specific...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391068/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391068/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/vwRIXQCHPR8" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/disease/cancer">cancer</category>
 <category domain="http://biomarkercommons.org/disease/cutaneous-t-cell-lymphoma">cutaneous T-cell lymphoma</category>
 <category domain="http://biomarkercommons.org/disease/non-hodgkins-lymphoma">non-Hodgkin's lymphoma</category>
 <category domain="http://biomarkercommons.org/organization/valirx">ValiRx</category>
 <category domain="http://biomarkercommons.org/term/oncology-therapeutics">oncology therapeutics</category>
 <category domain="http://biomarkercommons.org/term/patent-approval">patent approval</category>
 <category domain="http://biomarkercommons.org/term/personalized-medicine">personalized medicine</category>
 <pubDate>Tue, 15 May 2012 17:52:19 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">739 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30391068/0/biomarker-news~New-US-Patent-Grant-for-ValiRx%e2%80%99s-Cancer-Screening-Gene-Biomarker</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30391068/0/biomarker-news"&gt;&lt;p&gt;ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that a method for cancer screening, using specific...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391068/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391068/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/thermo-fisher-scientific-acquires-all-rights-for-pre-eclampsia-biomarker-from-nephromics</feedburner:origLink>
 <title>Thermo Fisher Scientific Acquires All Rights for Pre-eclampsia Biomarker from Nephromics</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/mkg3Ai9gpI8/biomarker-news~Thermo-Fisher-Scientific-Acquires-All-Rights-for-Preeclampsia-Biomarker-from-Nephromics</link>
 <description>&lt;p&gt;Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391069/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391069/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/mkg3Ai9gpI8" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/biomarker/placental-growth-factor">placental growth factor</category>
 <category domain="http://biomarkercommons.org/biomarker/plgf">PlGF</category>
 <category domain="http://biomarkercommons.org/disease/eclampsia">eclampsia</category>
 <category domain="http://biomarkercommons.org/disease/pre-eclampsia">pre-eclampsia</category>
 <category domain="http://biomarkercommons.org/organization/nephromics">Nephromics</category>
 <category domain="http://biomarkercommons.org/organization/thermo-fisher-scientific">Thermo Fisher Scientific</category>
 <category domain="http://biomarkercommons.org/term/patent-license">patent license</category>
 <category domain="http://biomarkercommons.org/term/screening">screening</category>
 <pubDate>Tue, 15 May 2012 17:46:43 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">738 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30391069/0/biomarker-news~Thermo-Fisher-Scientific-Acquires-All-Rights-for-Preeclampsia-Biomarker-from-Nephromics</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30391069/0/biomarker-news"&gt;&lt;p&gt;Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30391069/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30391069/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/opko-health-enters-into-license-agreement-with-international-health-technology-for-next-generation-prostate</feedburner:origLink>
 <title>OPKO Health Enters into License Agreement with International Health Technology for Next Generation Prostate Cancer Biomarker Panel</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/QjmV-704Rkw/biomarker-news~OPKO-Health-Enters-into-License-Agreement-with-International-Health-Technology-for-Next-Generation-Prostate-Cancer-Biomarker-Panel</link>
 <description>&lt;p&gt;OPKO Health, Inc. (NYSE:OPK) today announced execution of a license agreement granting International Health Technology, Ltd. (Cambridge, England) the right to offer OPKO's novel panel of kallikrein...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30201298/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30201298/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/QjmV-704Rkw" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/biomarker/kallikrein">kallikrein</category>
 <category domain="http://biomarkercommons.org/disease/cancer">cancer</category>
 <category domain="http://biomarkercommons.org/disease/prostate-cancer">prostate cancer</category>
 <category domain="http://biomarkercommons.org/organization/international-health-technology">International Health Technology</category>
 <category domain="http://biomarkercommons.org/organization/opko-health">OPKO Health</category>
 <category domain="http://biomarkercommons.org/term/license-agreement">license agreement</category>
 <category domain="http://biomarkercommons.org/term/prostate">prostate</category>
 <category domain="http://biomarkercommons.org/term/prostate-biopsy">prostate biopsy</category>
 <pubDate>Tue, 08 May 2012 00:07:25 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">737 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30201298/0/biomarker-news~OPKO-Health-Enters-into-License-Agreement-with-International-Health-Technology-for-Next-Generation-Prostate-Cancer-Biomarker-Panel</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30201298/0/biomarker-news"&gt;&lt;p&gt;OPKO Health, Inc. (NYSE:OPK) today announced execution of a license agreement granting International Health Technology, Ltd. (Cambridge, England) the right to offer OPKO&amp;#039;s novel panel of...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30201298/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30201298/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
<item><feedburner:origLink>http://biomarkercommons.org/biomarker-news/genomic-health-and-oncomed-announce-strategic-alliance-for-biomarker-research-and-discovery-using-next-generation</feedburner:origLink>
 <title>Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing</title>
 <link>http://feedproxy.google.com/~r/biomarker-funding-announcements/~3/l_OayDUhubM/biomarker-news~Genomic-Health-and-OncoMed-Announce-Strategic-Alliance-for-Biomarker-Research-and-Discovery-Using-Next-Generation-Sequencing</link>
 <description>&lt;p&gt;Genomic Health, Inc. (Nasdaq: GHDX) and OncoMed Pharmaceuticals, Inc. (OncoMed) today announced a strategic alliance to use Next Generation Sequencing (NGS) to identify biomarkers that can be applied...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30201299/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30201299/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/biomarker-funding-announcements/~4/l_OayDUhubM" height="1" width="1"/&gt;</description>
 <category domain="http://biomarkercommons.org/disease/breast-cancer">breast cancer</category>
 <category domain="http://biomarkercommons.org/disease/cancer">cancer</category>
 <category domain="http://biomarkercommons.org/disease/colon-cancer">colon cancer</category>
 <category domain="http://biomarkercommons.org/disease/colorectal-cancer">colorectal cancer</category>
 <category domain="http://biomarkercommons.org/disease/lung-cancer">lung cancer</category>
 <category domain="http://biomarkercommons.org/disease/prostate-cancer">prostate cancer</category>
 <category domain="http://biomarkercommons.org/organization/genomic-health">Genomic Health</category>
 <category domain="http://biomarkercommons.org/organization/oncomed">OncoMed</category>
 <category domain="http://biomarkercommons.org/term/alliance">alliance</category>
 <category domain="http://biomarkercommons.org/term/antibody-cancer-therapeutic">antibody cancer therapeutic</category>
 <category domain="http://biomarkercommons.org/term/next-generation-sequencing-0">next generation sequencing</category>
 <category domain="http://biomarkercommons.org/term/xenograft-model">xenograft model</category>
 <pubDate>Tue, 08 May 2012 00:01:42 +0000</pubDate>
 <dc:creator>Biomarker Commons Newsbot</dc:creator>
 <guid isPermaLink="false">736 at http://biomarkercommons.org</guid><feedburner:origLink>http://feeds.feedblitz.com/~/30201299/0/biomarker-news~Genomic-Health-and-OncoMed-Announce-Strategic-Alliance-for-Biomarker-Research-and-Discovery-Using-Next-Generation-Sequencing</feedburner:origLink></item><content:encoded>&lt;p&gt;&lt;Img align="left" border="0" height="1" width="1" style="border:0;float:left;margin:0;padding:0" hspace="0" src="http://feeds.feedblitz.com/~/i/30201299/0/biomarker-news"&gt;&lt;p&gt;Genomic Health, Inc. (Nasdaq: GHDX) and OncoMed Pharmaceuticals, Inc. (OncoMed) today announced a strategic alliance to use Next Generation Sequencing (NGS) to identify biomarkers that can be applied...&lt;p style="clear:left"&gt;&lt;a href="http://feeds.feedblitz.com/~/30201299/0/biomarker-news"&gt;Read the whole entry...&lt;/a&gt;&amp;nbsp;&lt;!-- _!fbztxtlnk!_ http://feeds.feedblitz.com/~/30201299/0/biomarker-news --&gt;&amp;raquo;&lt;/p&gt;</content:encoded>
</channel></rss>

